QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TEVA

QT67Teva Pharmaceutical Industries Limited
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·IL
Latest market price
31.48
-1.08-3.32%
OverviewShort InterestFilings
TEVAQT67Teva Pharmaceutical Industries Limited·NYSE
OverviewShort InterestFilings
31.48-3.32%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86AMRX-0.43%$16.21
Snapshot
Index-P/E23.83EPS (ttm)
1.33
Insider Own0.74%
Shs Outstand1.16B
Perf Week-8.91%
Market Cap37.82BForward P/E10.19EPS next Y3.09Insider Trans0.34%Shs Float-Perf Month-7.60%
Enterprise Value51.11BPEG0.01EPS next Q0.53Inst Own-Short Float-Perf Quarter6.93%
Income1.59BP/S2.17EPS this Y64.38%Inst Trans-Short Ratio-Perf Half Y4.58%
Sales17.44BP/B4.52EPS next Y41.37%ROA3.90%Short Interest-Perf YTD0.87%
Book/sh7.07P/C15.40EPS next 5Y18.77%ROE20.79%52W High37.35 -15.72%Perf Year86.38%
Cash/sh3.21P/FCF19.98EPS past 3/5Y-ROIC11.53%52W Low14.99 110.01%Perf 3Y-
Dividend Est.-EV/EBITDA15.40Sales past 3/5Y4.96% 0.71%Gross Margin51.98%Volatility2.28% 2.25%Perf 5Y-
Dividend TTM-EV/Sales2.93EPS Y/Y TTM302.07%Oper. Margin19.44%ATR (14)1.18Perf 10Y-
Dividend Ex-DateNov 27, 2017Quick Ratio0.78Sales Y/Y TTM4.86%Profit Margin9.03%RSI (14)37.19Recom2.17
Dividend Gr. 3/5Y-14.63% -3.84%Current Ratio1.01EPS Q/Q1.92%SMA20-7.07%Beta0.88Target Price40.00
Payout0.00%Debt/Eq2.05Sales Q/Q2.31%SMA50-6.39%Rel Volume1.91Prev Close32.56
Employees37,000LT Debt/Eq1.97EarningsJul 29SMA2009.47%Avg Volume6.38MPrice31.48
IPO DateFeb 16, 1982Option/ShortYes / YesEPS/Sales Surpr.6.00% 5.15%Net Debt/EBITDA4.00Volume12,193,930Change-3.32%
Analyst Ratings
DateActionAnalystRatingTarget
May-06-26ReiteratedBarclaysOverweight$38 → $40
Apr-30-26ReiteratedUBSBuy$28 → $42
Apr-30-26ReiteratedPiper SandlerOverweight$41 → $42
Mar-04-26ReiteratedPiper SandlerOverweight$40 → $41
Jan-30-26ReiteratedBarclaysOverweight$35 → $38
Jan-29-26ReiteratedScotiabankSector Outperform$35 → $40
Jan-07-26ReiteratedTruist Financial$32 → $36
Jan-06-26ReiteratedJefferiesBuy$14 → $40
Dec-22-25ReiteratedPiper SandlerOverweight$23 → $40
Dec-08-25InitiatedBarclaysOverweight$28 → $35
Latest News
Jun-16-26
Jun-16-2608:50AM
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid OverdoseBenzinga
Jun-08-26
Jun-08-2605:27PM
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To ComeSeekingAlpha
05:27PM
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To ComeSeekingAlpha
12:08PM
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
12:08PM
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
12:08PM
Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
08:02AM
Teva Pharma Announces New Data Highlighting Comprehensive Tardive Dyskinesia Symptom Improvement From Treatment With AUSTEDO And AUSTEDO XRBenzinga
08:02AM
Teva Pharma Announces New Data Highlighting Comprehensive Tardive Dyskinesia Symptom Improvement From Treatment With AUSTEDO And AUSTEDO XRBenzinga
08:02AM
Teva Pharma Announces New Data Highlighting Comprehensive Tardive Dyskinesia Symptom Improvement From Treatment With AUSTEDO And AUSTEDO XRBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue17,34817,25716,544
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A8,3178,3208,481
Gross Profit9,0348,9388,063
Selling, General and Administrative Excl. Other4,0523,9733,702
Research and Development9891,0131,055
Other Operating Expense1,7011,7943,609
Operating Income2,2892,157-303
Interest Expense905916941
Unusual Expense
———
Non-Operating Income (Expense)1818-3,675
Net Income Before Taxes1,3791,238-1,283
Income Taxes-187-180676
Consolidated Net Income1,5641,410-1,639
Net Income From Continuing Operations1,5661,418-1,959
Net Income1,5641,410-1,639
EPS (Recurring)1.371.23-1.45
EPS (Basic, Before Extraordinaries)1.371.23-1.45
EPS (Diluted)1.331.20-1.45
EBITDA3,2703,1414,431
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio23.6726.01—
Price To Sales Ratio2.102.08—
Gross Margin52.0851.7948.74
Operating Margin13.1912.50-1.83
Net Margin9.028.17-9.91
Shares Outstanding1,1561,1491,131
Market Capitalization36,39135,860—
Operating Lease Expense
———
Insider Trading Volume
$32.92$29.80$26.68$23.55$20.43● Close Price0.00M7.30M14.60M21.90M29.20MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kalif Eliyahu SharonEVP, Chief Financial OfficerJun 11 '26Sale34.10106,5633,633,30865,621Jun 16 12:00 AM
Lichtenstein ChenDirectorJun 05 '26Option Exercise0.0028,984019,296Jun 08 12:00 AM
BARER SOL JDirectorJun 05 '26Option Exercise0.0043,4780448,011Jun 08 12:00 AM
Crane Rosemary ADirectorJun 05 '26Option Exercise0.0028,9840127,739Jun 08 12:00 AM
Elstein AmirDirectorJun 05 '26Option Exercise0.0028,98402,118,455Jun 08 12:00 AM
LIEBERMAN GERALD MDirectorJun 05 '26Option Exercise0.0028,9840130,149Jun 08 12:00 AM
Nisen PerryDirectorJun 05 '26Option Exercise0.0028,9840119,807Jun 08 12:00 AM
Satchi-Fainaro RonitDirectorJun 05 '26Option Exercise0.0028,9840112,401Jun 08 12:00 AM
Zaks Tal ZviDirectorJun 05 '26Option Exercise0.0028,984073,264Jun 08 12:00 AM
MIGNONE ROBERTODirectorJun 05 '26Option Exercise0.0028,9840119,807Jun 08 12:00 AM
Francis Richard DPresident and CEOJun 05 '26Option Exercise0.0026,08601,183,682Jun 08 12:00 AM
Francis Richard DPresident and CEOJun 05 '26Sale34.356,153211,3561,177,529Jun 08 12:00 AM
Shields MatthewEVP, Global OperationsJun 03 '26Option Exercise0.0032,390032,392Jun 04 12:00 AM
Shields MatthewEVP, Global OperationsJun 03 '26Sale32.8716,195532,3309,989Jun 04 12:00 AM
Lippman EvanEVP, Business DevelopmentMay 14 '26Sale35.5841,6581,482,3676,095May 18 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR